Replies to post #566925 on NorthWest Biotherapeutics Inc (NWBO)

[Jackxkr]

So bad when nevercure is eating your lunch.

[Dr Bala]

How is the postdoc nonsense going at Cardiff?

[dstock07734]

Still hold conviction in NVCR. Here is something fishy.

On January 5, NVCR had vague PR. Look what the management was busy doing.



On January 9, NVCR released the 4th quarter report in which it said over three months they just recruit 10 new patients.

Did you smell anything wrong?

[dstock07734]

You need to read the JAMA paper carefully. This is what was mentioned in the paper. Anyone who has common senses know what it means.

"Eight of the 232 patients (3.4%) receiving DCVax-L were treated with tumor-treating fields (TTF) following recurrence. Four of those 8 patients (50.0%) continued receiving DCVax-L while using the TTF device after recurrence and survived from 22.6 to more than 72.7 months from randomization. Four of the 8 patients (50.0%) stopped receiving DCVax-L while using the TTF device post-recurrence, and survived from 8.9 to 29.2 months from randomization."

Don't get up your hope too much on the NSCLC trial. Can the armor thinge get T-cell infiltrate into tumor tissue? The answer is no. If there are no t cells, how could checking point inhibitors work? Is it simple enough to understand?

[dstock07734]

Here is the picture from the combo trial which from one perspective corroborated that the DCVax-L trial is a huge success.

Using pd-1 inhibitors first and DCVax-L later yields significantly more poor results than the case when the administration order was reversed, which clearly show that first DCVax-L can cause massive t-cell infiltration into the tumor in brain because dendritic cell instructions are well received, and second t-cells have to exist in the tumor tissue in order for pd-1 inhibitors to work.

[Roman516]

At the same time data from DCVax-L and DCVax-D could present leading indicators for advanced solid tumor and the overall survival rates could very well indicate even more positive results that are exceeding all expectations. In other words, DCVax products may even address many other solid tumor problems. Great news for other cancer patients, IMPO.
As for Novocare, nice! As for NWBO, WOW, Fantastic, IMPO.

[Hspooner]

Jon Doe, I commend you for presenting such great information on NVCR, but unfortunately human nature dictates that the majority of patients will not have the tenacity to stick with such a draconian treatment that NVCR has to offer, especially when the end game is ultimately the same, death!!

[biosectinvestor]

Data has already been presented, multiple times and published. Novocure has not published this data.

[dstock07734]

I doubt any patients would like wearing something like this if there is a better alternative.

[Dr Bala]

Best to go to a better school. The post displays a lack of basic understanding of GBM. There are so many great schools in London. Also query Dr. Keymour Ashkan. He can straighten you out on the basic issues.